Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy

Status Completed

Clinical Trial Summary

OBJECTIVES: I. Determine the response in plasma norepinephrine concentration and plasma glycerol to the agonist (clonidine) and the antagonist (yohimbine) of the alpha-2 adrenergic receptor in 6 patients with regional lipoatrophy and in 6 controls.

II. Determine the full sequence of the alpha-2 adrenergic receptor structural gene in genomic DNA from peripheral blood leukocytes.

Clinical Trial Description

PROTOCOL OUTLINE: Antihypertensives are held, beginning 3 days before the first study day.

An oral challenge is administered as follows: clonidine on day 1, yohimbine on day 2. The order of administration is reversed in alternate subjects.

Timed measurements of norepinephrine, glycerol, and free fatty acids follow each challenge. Structural gene sequencing is evaluated for each participant. ;

Study Design

Primary Purpose: Screening

Related Conditions & MeSH terms

Lipodystrophy

Clinical Trial Details

NCT number	NCT00004329
Study type	Observational
Source	National Center for Research Resources (NCRR)
Contact
Status	Completed
Phase	N/A
Start date	November 1999

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05419037` - Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy
Recruiting	`NCT03059121` - The Cleveland Cardiometabolic Cohort
Completed	`NCT00656175` - Raltegravir Therapy for Women With HIV and Fat Accumulation	Phase 2
Completed	`NCT00202241` - The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS	N/A
Completed	`NCT00006185` - Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome	Phase 1
Recruiting	`NCT02262832` - Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy	Phase 3
Completed	`NCT01679197` - Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy	Phase 2
Completed	`NCT02647853` - Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers	Phase 1
Active, not recruiting	`NCT00715546` - Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy	Phase 1
Completed	`NCT00069004` - A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth	N/A
Completed	`NCT00025883` - Leptin to Treat Lipodystrophy	Phase 2
Completed	`NCT00001142` - Metabolism and Body Shape of Healthy Children and Children With Chronic Infections	N/A
Active, not recruiting	`NCT02262806` - Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy	Phase 2
Completed	`NCT02258685` - Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients.
Completed	`NCT00192621` - Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects	Phase 4
Completed	`NCT00006190` - A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy	Phase 4
Recruiting	`NCT05930106` - Carotid Doppler Peak Velocity Variation in Liposuction Fluid Management	N/A
Recruiting	`NCT04656054` - Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance
Completed	`NCT00082628` - Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients	Phase 3
Withdrawn	`NCT01788462` - Egrifta Replacement and Sleep Disordered Breathing	N/A